* Phytopharm gets FDA go-ahead for Phase II trial of Cogane
* Oxford BioMedica reports positive two-year ProSavin data
* Phytopharm's shares up 10 pct, Oxford gives up gains
http://www.reuters.com/article/idUSLDE65D0OF20100614
We can only wait and hope but not count on it unfortunately.
Imad